Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
about
Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysisProspects for dengue vaccines for travelersThe dengue vaccine pipeline: Implications for the future of dengue controlDengue Fever: Causes, Complications, and Vaccine StrategiesRecent advances in understanding dengueGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineEarly Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human PrimatesVaccines and immunization strategies for dengue preventionDengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introductionHistorical Perspectives on Flavivirus ResearchDefining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting.The burden of dengue and chikungunya worldwide: implications for the southern United States and CaliforniaEfficacy and community effectiveness of larvivorous fish for dengue vector control.Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study.Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsCD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.RNA-based viral vectors.Characterization of oligonucleotide aptamers targeting the 5'-UTR from dengue virus.Working towards dengue as a vaccine-preventable disease: challenges and opportunities.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Dengue vaccines: what we know, what has been done, but what does the future hold?Potential for treatment and a Zika virus vaccine.Vaccines licensed and in clinical trials for the prevention of dengue.Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.Development of Peptide Vaccines in Dengue.Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.Inactivation of Dengue and Yellow Fever viruses by heme, cobalt-protoporphyrin IX and tin-protoporphyrin IX.A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.Dengue infection.Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design?Zika Virus Vaccine Development.Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
P2860
Q24288742-5085D988-D9F7-4C13-AEFD-FBF61FA89560Q26314423-6C369750-0666-471B-B831-80546BB4CA54Q26314683-314C7877-8DF5-4888-918F-C97ADF2E18A2Q26700082-BB821052-29BF-4607-96FE-64A24AFE47B6Q26766156-4F2913E9-7266-4D59-BB29-7093D3B37D9AQ26782367-447E6C7F-0F4B-4E8E-A7A3-A10E63AB24A6Q27303669-9A5E9917-4EAD-49A7-9BFF-98110B9C0E31Q28077521-3977FBAA-AE6F-47FE-9C19-FC3120AD6A86Q28950695-7026E547-1114-42C1-82E9-3348689D750AQ29994534-87378C46-730F-4651-98DD-60922E4F9E15Q33425879-D0D4581D-1DBB-4413-9255-B6B641674490Q33650118-C44E438C-3D82-4897-A33A-534E17B8835AQ34238916-F0E322BC-BC51-41FD-9795-3B51DB26CA86Q35574035-09AEC459-0042-4C8F-8F19-21FA1A67940DQ35594746-7220FD55-7477-44D0-A3D0-0FD0996C2FFCQ35627263-9DF29689-483D-411B-8041-9249CDD62025Q35742387-F27A0C20-924C-4987-B908-12E0DAA55F9FQ35781300-B2CF492B-7F88-498D-B926-7A334970BB8EQ36024479-8D8B44C2-6ABE-4F97-AD9E-4B6467E32473Q36181531-72C32EC8-2C8C-4F7F-99BF-0FAC11A9FB05Q36208591-EB242E78-C0F1-40D3-BB44-2884BE4C05D8Q38266413-9111B801-C63B-40F6-9C44-DB7CAA48A7C8Q38288377-9B10C53D-8AD0-4FA5-A807-A72F3FE6C285Q38657783-AC699B2F-F136-4AB2-9A53-40F7E09C91D4Q38658737-74151D3C-4532-4A54-B794-2E4CFCA34CA2Q38960985-0A745526-E22C-43E3-8DAC-6A6B5AFEFE04Q39025905-D6046BC8-F6BF-4262-BAA2-8A59E85016BFQ39172722-5923BB0F-D076-45FF-8B34-7213B773C0BDQ39468688-FFA77D3A-7894-445C-A1C6-BB93D06F386EQ40038715-A6D26539-563D-47DC-8892-4D218A01C2ACQ40042772-3049968D-A7BF-4F20-8DDA-4079CF546984Q40123101-131D1F92-2B9D-4E1D-B930-3986C1FA9A69Q42977175-B2326EC3-9843-4AA1-90C8-8368A6206BEEQ42996339-0550B5CB-6BF4-4614-A0AE-7C8AD8946BF1Q43038900-0D987DAB-6D82-494D-897C-8548376C2C28Q47006432-FE645999-921E-46A2-977C-B8C8EE467674Q54260853-877821FF-4DCE-41E2-B780-B7A083B7D12C
P2860
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@ast
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@en
type
label
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@ast
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@en
prefLabel
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@ast
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@en
P2093
P2860
P921
P1476
Safety and immunogenicity of a ...... cebo-controlled, phase 1 study
@en
P2093
Alejandra Jimenez
Aurelia A Haller
Betty E Luy
Claire Y-H Huang
Cynthia Thomson
Gilad S Gordon
Ivan D Velez
Jaclyn Scott
Janae L Stovall
John Arguello
P2860
P304
P356
10.1016/S1473-3099(14)70811-4
P577
2014-07-23T00:00:00Z